These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25185962)

  • 41. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
    Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
    Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.
    Garcia-Doval I; Descalzo MA; Mason KJ; Cohen AD; Ormerod AD; Gómez-García FJ; Cazzaniga S; Feldhamer I; Ali H; Herrera-Acosta E; Griffiths CEM; Stern RS; Naldi L;
    Br J Dermatol; 2018 Oct; 179(4):863-871. PubMed ID: 29723914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
    Lluch-Galcerá JJ; Carrascosa JM; González-Quesada A; Rivera-Díaz R; Sahuquillo-Torralba A; Llamas-Velasco M; Gómez-García FJ; Herrera-Acosta E; de la Cueva P; Baniandrés-Rodríguez O; Lopez-Estebaranz JL; Belinchón I; Ferrán M; Mateu A; Rodríguez L; Riera-Monroig J; Abalde-Pintos MT; Carretero G; García-Donoso C; Pujol-Marco C; Del Alcázar E; Santamaría-Domínguez C; Suárez-Pérez JA; Nieto-Benito LM; Ruiz-Genao DP; Salgado-Boquete L; Descalzo MÁ; García-Doval I
    Br J Dermatol; 2024 Feb; 190(3):355-363. PubMed ID: 37846976
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis.
    Hayashi M; Umezawa Y; Fukuchi O; Ito T; Saeki H; Nakagawa H
    J Dermatol; 2014 Nov; 41(11):974-80. PubMed ID: 25346301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries.
    Garcia-Doval I; Cohen AD; Cazzaniga S; Feldhamer I; Addis A; Carretero G; Ferrándiz C; Stern RS; Naldi L;
    J Am Acad Dermatol; 2017 Feb; 76(2):299-308.e16. PubMed ID: 27693008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.
    van Lümig PP; Driessen RJ; Roelofs-Thijssen MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2011 Aug; 165(2):375-82. PubMed ID: 21428975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
    Papp KA; Strober B; Augustin M; Calabro S; Londhe A; Chevrier M;
    J Drugs Dermatol; 2012 Oct; 11(10):1210-7. PubMed ID: 23134986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biologic treatments for elderly patients with psoriasis.
    Momose M; Asahina A; Hayashi M; Yanaba K; Umezawa Y; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1020-1023. PubMed ID: 28439956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
    López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
    Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. German psoriasis registry PsoBest: objectives, methodology and baseline data.
    Augustin M; Spehr C; Radtke MA; Boehncke WH; Luger T; Mrowietz U; Reusch M; Strömer K; Wozel G; von Kiedrowski R; Rustenbach SJ; Purwins S; Reich K
    J Dtsch Dermatol Ges; 2014 Jan; 12(1):48-57. PubMed ID: 24393314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.
    Pérez-Plaza A; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Rivera R; Jiménez-Puya R; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1021-1028. PubMed ID: 28252811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression? It's the Disease NOT the Drug.
    Kircik LH
    J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
    van den Reek JMPA; Seyger MMB; van Lümig PPM; Driessen RJB; Schalkwijk CJM; Berends MAM; van de Kerkhof PCM; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):615-623. PubMed ID: 29121430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric psoriasis: updates in biologic therapies.
    Sukhatme SV; Gottlieb AB
    Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.